A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trialGilberto de Castro, Nils Gunnar Skare, D. Grabarz et al.|European Journal of Cancer|2017Cited by 57
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Fabrice André, Komal Jhaveri, Erika Hamilton et al.|Journal of Clinical Oncology|2024Cited by 32